<DOC>
	<DOCNO>NCT01413230</DOCNO>
	<brief_summary>Systemic Lupus Erythematosus ( SLE ) systemic autoimmune disorder . It mainly involve skin , joint , nervous system kidney may life threaten . SLE associated production autoantibody perturbation regulatory T cell T helper lymphocytes produce interleukin ( IL ) -17 ( Th17 cell ) . Treatments include corticosteroid , hydroxychloroquine immunosuppressive agent . Immunomodulatory effect vitamin D supplementation VITRO recently describe , notably expansion Treg able suppress inflammatory response mediate CD4+ CD8+ T cell decrease Th17 cell .</brief_summary>
	<brief_title>Vitamin D Supplementation Systemic Lupus Erythematosus</brief_title>
	<detailed_description>Systemic Lupus Erythematosus ( SLE ) systemic autoimmune disorder . It mainly involve skin , joint , nervous system kidney may life threaten . SLE associated production autoantibody perturbation regulatory T cell T helper lymphocytes produce interleukin ( IL ) -17 ( Th17 cell ) . Treatments include corticosteroid , hydroxychloroquine immunosuppressive agent . Immunomodulatory effect vitamin D supplementation VITRO recently describe , notably expansion Treg able suppress inflammatory response mediate CD4+ CD8+ T cell decrease Th17 cell . Objective : To evaluate cellular immune response vitamin D supplementation patient SLE . Methods : This open prospective trial . SLE patient hypovitaminosis D ( &lt; 30 ng/mL ) receive vitamin D supplementation . 100 000 UI cholecalciferol per week 4 week 100 000 UI cholecalciferol per month 6 month administer . All patient follow begin vitamin D supplementation month 2 month 6 . End point : 1 . Clinical biological tolerance : Absence hypercalcemia lithiasis vitamin D supplementation . 2 . Immunologic follow-up T cell B cell homeostasis ( include Treg Th17 ) gene expression profile PBMCs use TRANSCRIPTOMIC analysis , , vitamin D supplementation . 3 . Clinical efficacy : follow-up clinical manifestation SLE disease activity score ( SLEDAI ) vitamin D supplementation . Schedule : Duration patient ' inclusion period estimate 3</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Systemic lupus erythematosus Age &gt; 18 year Serum vitamin D level [ 25 ( OH ) D ] &lt; 30 ng/mL Low moderate active disease without modification associate treatment Pregnancy Serum 25 ( OH ) D level &gt; 30 ng/mL Flare require modification treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Systemic lupus erythematosus</keyword>
	<keyword>vitamin D supplementation</keyword>
	<keyword>regulatory T cell</keyword>
	<keyword>Th17 cell</keyword>
</DOC>